Presentation is loading. Please wait.

Presentation is loading. Please wait.

Marginal dissection for mid-sized pituitary adenomas

Similar presentations


Presentation on theme: "Marginal dissection for mid-sized pituitary adenomas"— Presentation transcript:

1 Marginal dissection for mid-sized pituitary adenomas
Andrew Law Marginal dissection for mid-sized pituitary adenomas

2 Goals Maximise tumour resection Maximise functional cure rates
Minimise recurrence Reduce need for Radiotherapy Not affect rates of hypopituitarism Minimise complication rates

3 Pure endoscopic technique
Began in Endoscopic approach / Septal pushover  Microscope for tumour resection Progression to - Pure endoscopic surgery 2007 Technique Improved camera / monitor systems Liquid coagulants Approx 50% with ENT - Functioning - Difficult cases

4 Complications of Transsphenoidal Surgery: Results of a National Survey, Review of the Literature, and Personal Experience Ciric, Ivan MD; Ragin, Ann PhD; Baumgartner, Craig PA-C, MBA; Pierce, Debi BS Neurosurgery Issue: Volume 40(2), February 1997, pp

5 Exposure Utilisation of pseudo-capsule
Actual dissection of adenomas Utilisation of pseudo-capsule E Oldfield Using sublabial / microscopic approach Extending to Endoscopic approach

6 Surgical Management of Cushing’s Disease:
A Personal Perspective Edward H. Oldfield, MD Clinical Neurosurgery Volume 58, 2011

7 Pituitary Series Andrew Law 681 Pituitary Tumour Operations (to Sept 15) (Excluding meningiomas/craniopharyngiomas/others) Non Functioning 460 Functioning 221 FU 3m-15yrs

8 GH secreting tumours

9

10

11

12

13 GH secreting tumour operations
Total

14 GH 2012-2015 38 Operations (34 patients)
4 repeat surgery 2 cured / 2 ongoing Biochem cure (Surgery alone) – (54%) Biochem cure (Surgery +/- Octreotide LAR +/- DXT) (88%) (2 cases awaiting response to Rx) 1 uncontrolled progression  Death Long term remission rate – 80%

15 Issues Mixed tumours GH-PL Preoperative medications Difficult tumours
Cabergoline Octreotide Some evidence that may improve cure rates But increases surgical difficulty Difficult tumours Size Cavernous sinus invasion Sphenoid anatomy

16

17

18

19 ACTH Tumours 2000-2011 59 Remission 50 85%
Total 78 Visible microadenomas 100% Cavernous sinus invasion Stereotactic radiosurgery “Invisible microadenomas” Near total “85%”gland resection Tumour outside pituitary fossa

20

21 Non-Functioning Adenomas 2012-15
Early MRI (3/12) – 0 cases of significant residual (sellar/suprasellar) Postoperative DXT – 3 patients Recurrence rates?

22 CSF Leaks Intraoperative 46% Postoperative 4.8% 2000-2011 8.8%
(Req repacking surgery) Includes extended procedures 0 last 2 years %

23 Complications 2012-2015 No perioperative deaths
SIADH “Approx 30%” – At least Late postop abscess (post extended) - 1 Carotid puncture – Clipped - 1 Visual decline – 2 (Both for recurrence) Surgery abandoned due to sinus infection - 1 Sphenoid mucocoele - 1 Sinusitis – Common

24

25

26

27

28

29 Technique Exposure Arachnoid knife Rhoton dissector Ring curettes
Bony margins Stopping instrument contact. “Touch” Arachnoid knife Rhoton dissector Ring curettes Malleable endoscopic instruments Water dissection Micro patties Patience Microsurgical approach

30 Videos of the actual transphenoidal surgery are available to view.
If you are interested in seeing some real life action, please

31 Followup Imaging (MRI) Work in progress!! Functioning Non Functioning
Only if fail to cure – Biochemically Non Functioning (3m),1yr, 2yr, 4yr, 4yr More frequent if residual / recurrent tumour evident Work in progress!!


Download ppt "Marginal dissection for mid-sized pituitary adenomas"

Similar presentations


Ads by Google